Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmetec Plus combines an ARB with a thiazide diuretic to lower blood pressure through complementary mechanisms.

• Hypertension: helps achieve target blood pressure levels in adults.
• Heart failure: supports fluid management and blood pressure control when used as part of a broader regimen.
• Diabetic nephropathy: assists in reducing intraglomerular pressure, slowing kidney damage progression.

• Olmesartan medoxomil blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and further reducing circulating blood volume, together producing a synergistic antihypertensive effect.

Adverse reactions to Olmetec Plus are reported across a spectrum of frequency.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver enzyme elevations
• Blood dyscrasias (e.g., agranulocytosis)

Olmetec Plus should be used with careful clinical oversight, particularly in patients with certain comorbidities.

• Renal impairment: monitor kidney function and electrolytes regularly.
• Hepatic disease: use caution; adjust dosing if necessary.
• Electrolyte imbalance: check serum potassium and sodium levels.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Concomitant potassium‑sparing agents: risk of hyperkalemia, monitor closely.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmetec Plus may interact with several drug classes, requiring monitoring or avoidance.

Major Interactions (Avoid)

• Aliskiren (in diabetics): increased risk of renal dysfunction and hyperkalemia.
• Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase lithium levels, risking toxicity.
• Antidiabetic agents: enhanced glucose‑lowering effect, risk of hypoglycaemia.
• ACE inhibitors or other ARBs: additive effect on potassium and renal function.